In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 56 for your search:

Drug:  epoetin alfa
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase IV Study of Epoetin alfa in Women With Stage I, II, or III Breast Cancer and Chemotherapy-Related Anemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0011004, ORTHO-PR-00-27-012, ORTHO-PR-01-27-003, NCI-G01-2002, NCT00022386

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003541, NCT00216541

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

Phase: Phase IV
Type: Health services research, Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR002455, EPOCAN4015, NCT00264108

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Phase: Phase IV
Type: Natural history/Epidemiology, Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005596, EPOCAN4018, NCT00398749

Phase IIIB Open-Label, Controlled, Randomized Study to Identify a Single Subcutaneous Dose of PROCRIT (Epoetin alfa) That Can Be Given Weekly Rather Than the Standard Three-Times-Weekly Dose for the Treatment of Anemia in Cancer Subjects Receiving Platinum-Containing Chemotherapy (Summary Last Modified 05/98)

Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RWJPRI-EPO-CA-480, NCI-V96-0978

Phase III Randomized Study of Epoetin Alfa versus Placebo in Anemic Patients Receiving Chemotherapy for Stage IV Metastatic Breast Cancer (Summary Last Modified 02/1999)

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18-80
Sponsor: NCI
Protocol IDs: RPCI-DS-97-10, ORTHO-PR-96-27-004, NCI-G98-1394

Phase III Randomized Study of Epoetin Alfa in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Chemotherapy Related Mild or Moderate Anemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-97125, ORTHO-PR-96-27-031, RPCI-DS-97-38, NCI-G98-1436, NCT00003341

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066673, NCCTG-979253, NCI-P98-0133, 97-92-53, NCT00003600

Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067599, RTOG-9903, RTOG-DEV-1008, NCT00004917

10.

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000068641, GOG-0191, CAN-NCIC-CX4, CX4, NCT00017004

11.

Anemia in Patients With a Non-Myeloid Malignancy

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010101, UCLA-0201098, NCI-G02-2112, AMGEN-200101101, NCT00046982, NCT00038064

12.

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000288821, NCCTG-N02C2, NCT00058331

13.

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000301881, ECOG-E1Z01, E1Z01, NCT00060398

14.

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000333213, P30CA016042, UCLA-0306021, AMGEN-20030125, NCT00070382

15.

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003223, NCT00210587

16.

Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome

Phase: Phase III
Type: Treatment
Status: Closed
Age: 19 to 80
Sponsor: Other
Protocol IDs: OEGRO54, NCT00348738

17.

Phase III Randomized Study of Recombinant Epoetin Alfa or Epoetin Beta With Versus Without Parenteral Iron in Anemic, Iron-Replete Patients With Nonmyeloid Malignancies. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Supportive care
Status: Closed
Age: Over 16
Sponsor: Other
Protocol IDs: BARTS-06/Q0605/93, ISRCTN11830961, EU-20731, 06/Q0605/93, NCT00482716

18.

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Phase: Phase III
Type: Supportive care
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0890, NCT00656448

19.

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Phase: Phase III
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01173, ECOG-E2905, U10CA021115, E2905, NCT00843882

20.

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 60 and under
Sponsor: Other
Protocol IDs: MA21, CAN-NCIC-MA21, AMGEN-CAN-NCIC-MA21, NCCTG-CAN-NCIC-MA21, BMS-CAN-NCIC-MA21, JANSSEN-ORTHO-CAN-NCIC-MA21, PFIZER-CAN-NCIC-MA21, SWOG-CAN-NCIC-MA21, CDR0000068520, NCIC-MA21, NCT00014222

21.

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069148, CCCWFU-62299, CCCWFU-BG01-193, NCI-P01-0200, NCT00028938

22.

Epoetin Alfa With or Without Filgrastim Compared With Blood Transfusions in Treating Patients With Myelodysplastic Syndrome

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065907, ECOG-1996, E1996, NCT00003138

23.

Phase I/II Study of Escalating IL-6 with GM-CSF/EPO for Myelodysplastic Syndrome (Summary Last Modified 03/97)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RPMI-DS-9429, NCI-T94-0072D, T94-0072

24.

Phase I/II Randomized Pilot Study of G-CSF with vs without EPO in Sequential Intensified Regimens of CAE (CTX/DOX/VP-16), HIPE (High-Dose CDDP/VP-16), and PARE (CBDCA/VP-16)/ABMT Followed by IFN-A in Children with Advanced Neuroblastoma (Summary Last Modified 08/00)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 1 and over
Sponsor: NCI
Protocol IDs: SJCRH-NB-91, NCI-T91-0217D, T91-0217

25.

Phase II Study of VIP/VB (VBL/IFF/CDDP/VP-16/BLEO) with G-CSF and EPO in Male Patients with Advanced Germ Cell Tumors (Summary Last Modified 09/94)

Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: E-1893, E1893

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map